QT Interval in Patients With COVID-19
JAMA Cardiol
.
2021 Mar 1;6(3):357-358.
doi: 10.1001/jamacardio.2020.4955.
Authors
Ingrid Berling
1
2
,
Robert S Hoffman
3
,
Sophie Gosselin
4
Affiliations
1
Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.
2
Department of Emergency Medicine, Calvary Mater Newcastle, Newcastle, New South Wales, Australia.
3
Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, NYU Grossman School of Medicine, New York, New York.
4
Department of Emergency Medicine, CISSS Montérégie-Centre Hôpital Charles-LeMoyne, Greenfield Park, Québec, Canada.
PMID:
33084841
DOI:
10.1001/jamacardio.2020.4955
No abstract available
Publication types
Comment
MeSH terms
Azithromycin
COVID-19 Drug Treatment*
Humans
Hydroxychloroquine*
SARS-CoV-2
Substances
Hydroxychloroquine
Azithromycin